Exome Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Exome Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-61,673	Closed	-$2.06M	–	66
2026 Q1	$2.06M	Buy	+61,673	New	+$2.42M	1.07%	40
2025 Q4	–	Sell	-48,445	Closed	-$2.66M	–	85
2025 Q3	$3.27M	Buy	48,445 +6,804	+16%	+$504K	1.98%	18
2025 Q2	$3.49M	Sell	41,641 -1,800	-4%	-$135K	2.59%	12
2025 Q1	$3.1M	Sell	43,441 -33,844	-44%	-$1.65M	2.76%	11
2024 Q4	$3.47M	Buy	+77,285	New	+$4M	2.61%	16

Exome Asset Management's SLNO Position: Q2 2026 in Review

Exome Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 61,673 shares — an estimated $2.06M sold.

Exome Asset Management first reported a position in SLNO in Q4 2024 and held it in 5 quarters. The position peaked at $3.49M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Exome Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Exome Asset Management sold 61,673 Soleno Therapeutics shares in Q2 2026, an estimated $2.06M.
Exome Asset Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 5 quarters.
Exome Asset Management's Soleno Therapeutics position peaked at $3.49M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.